PharmiWeb.com - Global Pharma News & Resources
14-May-2019

New registration for Tri-Solfen® expands commercial reach in New Zealand

Label extension for the Group’s innovative pain mitigation product includes use on calves following disbudding procedure Government legislation in New Zealand to prohibit the disbudding of calves without appropriate analgesics from October 1st 2019 Tri-Solfen® is currently the only approved topical pain and wound management product for use in livestock undergoing painful husbandry procedures globally Melbourne, Australia – 13th May 2019 – Medical Ethics Pty Ltd (“Medical Ethics” or “the Group”), a commercial and product development company focused on pain mitigation in wounds for humans and animals, announces that with its New Zealand marketing and distribution partner Bayer Animal Health it has successfully registered Tri-Solfen® in New Zealand for hot iron cautery disbudding procedures in calves. This marks the fifth approval for the Group’s innovative pain mitigation product in animal husbandry procedures. Tri-Solfen® is a local anaesthetic and antiseptic gel spray that adheres well to wounds and acts as a barrier to environmental stimuli, promotes haemostasis and improve wound healing. The approval was granted by the Ministry for Primary Industries, New Zealand’s governing body for animal welfare, and precedes an upcoming change in legislation which will prohibit the disbudding of calves without appropriate analgesics. To remove potentially dangerous horns, over two million calves undergo painful hot iron disbudding procedures each year in New Zealand. Tri-Solfen® represents the only approved topical pain and wound management product for use in livestock undergoing such painful husbandry procedures globally. In conjunction with the approval, Bayer Animal Health hosted over 400 veterinarians for a launch event which highlighted the new use for Tri-Solfen®. The new commercial opportunity expands on the products’ existing remit which includes pain relief for certain livestock after tail docking and castration. Andrew Bosch, Brand Manager at Bayer Animal Health, commented: “Broadening the approved use of Tri-Solfen®, which is proven to deliver a highly effective, practical and cost-efficient solution for pain mitigation in animals, is a positive development in helping to ease some of the animal welfare pressures that face modern day farming communities. At Bayer Animal Health, we are committed to improving animal wellbeing by bringing best-in-class products to farmers and veterinarians and we continue to work with Medical Ethics on approvals for further indications and claims for Tri-Solfen® in New Zealand.” Allan Giffard, Managing Director of Medical Ethics, added: “With new legislation prohibiting the disbudding of calves without appropriate analgesics coming into force on the 1st of October 2019, this is an important registration for Tri-Solfen® as the only approved topical pain and wound management product for use in livestock undergoing such painful husbandry procedures. It is also another endorsement of our technology and dedication to improving animal welfare across the globe. We look forward to expanding our current offering in New Zealand, building on the enormous success in Australia and expanding our global market approvals with our international marketing partner Dechra Pharmacuticals.”

Editor Details

Last Updated: 16-May-2019